Table 1A
Control Group A
Sample ID MAST 1035 MAST 1261 MAST 1194 MAST 0931 MAST 0227
Date Collected 01/04/11 05/20/11 04/05/11 10/27/10 06/10/09
Diagnosis Date 12/28/10 4/28/11 3/18/11 8/15/07 5/29/09
Sarcoma pathological subtype Myxofibro-sarcoma Synovial Sarcoma Myxofibro-sarcoma PNST Leiomyo-sarcoma
Primary Lesion Site L Forearm Thigh R Thigh Thigh L Calf
Sample Lesion Site L Forearm L Thigh R Thigh Lung L Calf
Disease Status (Local vs. Metastatic) Local Local Local Metastatic Local
Prior Radiation (XRT) to Sample No No No Yes No
% Necrosis of Sample 0 0 0 0 0
PRE Collection Treatment None 1. Excision None Excision & XRT to primary None
Status Post Collect NED + lung met 6/21/11 + lung met 5/5/11 NED NED
POST Collection Treatment 2. XRT arm; 3. Obs 3. Ifos/Adria 2. XRT Obs 2. Gem/Tax
Ratio of MTDH/β-actin 0 1.04 1.23 0.18 1.22
HotAir (RNA) 1 846 10.5 112 77.2
Table 1B 
Control Group B
Sample ID MAST 1035 MAST 0850 MAST 0703 MAST 1139 MAST 0796
Date Collected 01/04/11 09/17/10 05/18/10 03/29/11 08/13/10
Diagnosis Date 12/28/10 6/15/10 7/9/09 10/4/07 2/17/06
Sarcoma pathological subtype Myxofibro-sarcoma Leiomyo-sarcoma Leiomyo-sarcoma Leiomyo-sarcoma Leiomyo-sarcoma
Primary Lesion Site L Forearm R Thigh Uterus Uterus L Groin
Sample Lesion Site L Forearm R Thigh Colon Abdomen Adrenal gland
Disease Status (Local vs. Metastatic) Local Local Metastatic Met, recurr Metastatic
Prior Radiation (XRT) to Sample No Yes No No Yes
% Necrosis of Sample 0 70% 100% 85% 5%
PRE Collection Treatment None 1. Cis/Adria/ Mito w/XRT 1. Hysterect 2. Gem/Tax 1. Hysterect 2. Gem/Tax 1. Gem/ tax; 2.Clin Trial; 3.Doxuribicin; 4.Dacarbazine
Status Post Collect NED PD Concurr Gem/Tax NED SD--slow growing
POST Collection Treatment 2. XRT arm; 3. Obs 3.Ifos 3. Gem/Tax; 4. Excision; 5. VPA 4. None, PD Obs
Ratio of MTDH/β-actin 0 0.38 0.17 0 0
HotAir (RNA) 1 149 -2.7 78 780
Table 1C
Control Group C
Sample ID MAST 1035 MAST 0006 MAST 0268 MAST 0510
Date Collected 01/04/11 11/19/08 07/10/09 01/22/10
Diagnosis Date 12/28/10 11/5/08 4/14/09 5/6/09
Sarcoma pathological subtype Myxofibro-sarcoma Lipo-sarcoma, Myxoid Malignant Fibrous Histiocytoma Leiomyo-sarcoma
Primary Lesion Site L Forearm Buttock Thigh L Leg
Sample Lesion Site L Forearm Buttock Lung Lung
Disease Status (Local vs. Metastatic) Local Metastatic Metastatic Metastatic
Prior Radiation (XRT) to Sample No No No No
% Necrosis of Sample 0 0 0 0
PRE Collection Treatment None None 1. Above knee amp 1. Amp; 2.Gem/ Tax; 3.Lung resection
Status Post Collect NED + other met sites + lung met 8/25/09 + lung met 4/30/11
POST Collection Treatment 2. XRT arm; 3. Obs None, PD None, PD None, PD
Ratio of MTDH/β-actin 0 0 2.1 1.62
HotAir (RNA) 1 36.4 0.8 0.7
Abbreviations: NED: No Evidence of Disease; XRT: Radiation; Obs: Observation; Amp: Amputation; L: Left; R: Right; PD: Progressive Disease; SD: Stable Disease;Gem: Gemcitabine; Ifos: Ifosfamide; Tax: Taxotere (Docetaxel Injection); Adria: Adriamycin
Table 1: Detailed description of disease status and treatments before and after sample collection in three groups of sarcoma subjects. Primary sarcoma subjects were shown in 1A, metastatic sarcoma subjects with reduced MTDH and high HOTAIR were shown in 1B, metastatic sarcoma subjects with variable MTDH and HOTAIR were shown in 1C.